{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T04:30:59Z","timestamp":1649133059424},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1097\/mop.0b013e328362fdfb","type":"journal-article","created":{"date-parts":[[2013,6,18]],"date-time":"2013-06-18T11:59:13Z","timestamp":1371556753000},"page":"502-508","source":"Crossref","is-referenced-by-count":2,"title":["Incretins and amylin in pediatric diabetes"],"prefix":"10.1097","volume":"25","author":[{"given":"Jamie R.","family":"Wood","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Silverstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-13-20210206","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1210\/jcem-24-10-1076","article-title":"Plasma insulin responses to oral and intravenous glucose administration.","volume":"24","author":"Elrick","year":"1964","journal-title":"J Clin Endocrinol Metab"},{"key":"R2-13-20210206","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1399-543X.2006.00159.x","article-title":"Newer therapeutic options for children with diabetes mellitus: theoretical and practical considerations.","volume":"7","author":"Jeha","year":"2006","journal-title":"Pediatr Diabetes"},{"key":"R3-13-20210206","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.drudis.2011.08.017","article-title":"The potential of incretin-based therapies in type 1 diabetes.","volume":"17","author":"Suen","year":"2012","journal-title":"Drug Dis Today"},{"key":"R4-13-20210206","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1172\/JCI116186","article-title":"Preserved incretin activity of glucagon-like peptide 1 7-36 amide but not of synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus.","volume":"91","author":"Nauck","year":"1993","journal-title":"J Clin Invest"},{"key":"R5-13-20210206","doi-asserted-by":"crossref","first-page":"7911","DOI":"10.1073\/pnas.93.15.7911","article-title":"Induction of intestinal epithelial proliferation by glucagon-like peptide 2.","volume":"93","author":"Drucker","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"R6-13-20210206","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.1210\/endo.136.11.7588257","article-title":"Regulation of glucagon-like peptide-1 (7-36) amide, peptide YY, and neurotensin secretion by neurotransmitters and gut hormones in the isolated vascularly perfused rat ileum.","volume":"136","author":"Dumoulin","year":"1995","journal-title":"Endocrinology"},{"key":"R7-13-20210206","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/ajcn\/77.3.605","article-title":"Differential effects of saturated and monounsaturated fats on postprandial lipemia and glucagon-like peptide 1 responses in patients with type 2 diabetes.","volume":"77","author":"Thomsen","year":"2003","journal-title":"Am J Clin Nutr"},{"key":"R8-13-20210206","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.regpep.2003.10.028","article-title":"Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes.","volume":"117","author":"Nielsen","year":"2004","journal-title":"Regul Pept"},{"key":"R9-13-20210206","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jamainternmed.2013.2720","article-title":"Glucagon like peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.","volume":"173","author":"Singh","year":"2013","journal-title":"JAMA Intern Med"},{"key":"R10-13-20210206","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1463-1326.2011.01365.x","article-title":"LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects.","volume":"13","author":"Barrington","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"R11-13-20210206","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1463-1326.2011.01512.x","article-title":"Proportion of patients with HbA1c target7 with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78945 patients.","volume":"14","author":"Esposito","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"R12-13-20210206","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/j.1463-1326.2011.01428.x","article-title":"Effects of exenatide twice daily versus sitagliptin on 24-h glucoregulatory and hormonal measures: a randomized, double-blind, crossover study.","volume":"13","author":"Berg","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"R13-13-20210206","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.diabres.2012.02.016","article-title":"Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure, and gastric emptying in type 2 diabetes.","volume":"97","author":"Horowitz","year":"2012","journal-title":"Diabetes Res Clin Prac"},{"key":"R14-13-20210206","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1185\/03007995.2012.707119","article-title":"Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea in Muslim patients during Ramadan: a randomized pragmatic study.","volume":"28","author":"Aravind","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"R15-13-20210206","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1185\/03007995.2012.703134","article-title":"Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a prespecified analysis adjusting for the most recently measured HbA1c value.","volume":"28","author":"Krobot","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"R16-13-20210206","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1542\/peds.2012-3494","article-title":"Management of newly diagnosed type 2 diabetes mellitus (T2DM) in children and adolescents.","volume":"131","author":"Copeland","year":"2013","journal-title":"Pediatrics"},{"key":"R17-13-20210206","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.2337\/dc11-1928","article-title":"Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin A1C targets.","volume":"35","author":"DeVries","year":"2012","journal-title":"Diabetes Care"},{"key":"R18-13-20210206","doi-asserted-by":"crossref","first-page":"955","DOI":"10.2337\/dc11-1434","article-title":"Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes.","volume":"35","author":"Rosenstock","year":"2012","journal-title":"Diabetes Care"},{"key":"R19-13-20210206","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1185\/03007995.2012.665046","article-title":"Effect of sitagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin.","volume":"28","author":"Barnett","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"R20-13-20210206","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/oby.2011.337","article-title":"Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized controlled pilot study.","volume":"20","author":"Kelly","year":"2012","journal-title":"Pediatric Obesity"},{"key":"R21-13-20210206","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1001\/jamapediatrics.2013.1045","article-title":"The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity.","volume":"167","author":"Kelly","year":"2013","journal-title":"JAMA Pediatr"},{"key":"R22-13-20210206","doi-asserted-by":"crossref","first-page":"959","DOI":"10.2337\/dc11-2424","article-title":"Effects of diet soda on gut hormones in youths with diabetes.","volume":"34","author":"Brown","year":"2012","journal-title":"Diabetes Care"},{"key":"R23-13-20210206","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.2337\/db10-0084","article-title":"Beta cell growth and regeneration: replication is only part of the story.","volume":"59","author":"Bonner-Weir","year":"2010","journal-title":"Diabetes"},{"key":"R24-13-20210206","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2337\/db07-1578","article-title":"Beta cell replication by loosening the brakes of glucagon-like peptide-1 receptor signaling.","volume":"57","author":"Schuit","year":"2008","journal-title":"Diabetes"},{"key":"R25-13-20210206","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1677\/JOE-10-0030","article-title":"Pancreas-specific GS alpha deficiency has divergent effects on pancreatic alpha- and beta-cell proliferation.","volume":"206","author":"Xie","year":"2010","journal-title":"J Endocrinol"},{"key":"R26-13-20210206","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1399-5448.2011.00812.x","article-title":"Proinsulin, GLP-1, and glucagon are associated with partial remission in children and adolescents with newly diagnosed type 1 diabetes.","volume":"13","author":"Kaas","year":"2012","journal-title":"Pediatr Diabetes"},{"key":"R27-13-20210206","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.2337\/dc09-1959","article-title":"The role of adjunctive exenatide therapy in pediatric type 1 diabetes.","volume":"33","author":"Raman","year":"2010","journal-title":"Diabetes Care"},{"key":"R28-13-20210206","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1073\/pnas.84.11.3881","article-title":"Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells.","volume":"84","author":"Westermark","year":"1987","journal-title":"Proc Natl Acad Sci USA"},{"key":"R29-13-20210206","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1152\/physrev.00042.2009","article-title":"Islet amyloid polypeptide, islet amyloid, and diabetes mellitus.","volume":"91","author":"Westermark","year":"2011","journal-title":"Physiol Rev"},{"key":"R30-13-20210206","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1055\/s-2002-34790","article-title":"The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus.","volume":"34","author":"Fineman","year":"2002","journal-title":"Horm Metab Res"},{"key":"R31-13-20210206","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1007\/s00125-005-1732-4","article-title":"Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes.","volume":"48","author":"Chapman","year":"2005","journal-title":"Diabetologia"},{"key":"R33-13-20210206","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1046\/j.1365-2982.2002.00311.x","article-title":"Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus.","volume":"14","author":"Vella","year":"2002","journal-title":"Neurogastroenterol Motil"},{"key":"R34-13-20210206","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1152\/advan.00167.2012","article-title":"Interactions between the central nervous system and pancreatic islet secretions: a historical perspective.","volume":"37","author":"Begg","year":"2013","journal-title":"Adv Physiol Educ"},{"key":"R35-13-20210206","doi-asserted-by":"crossref","first-page":"647","DOI":"10.33549\/physiolres.931995","article-title":"Gut peptide hormones and pediatric type 1 diabetes.","volume":"60","author":"Huml","year":"2011","journal-title":"Physiol Res"},{"key":"R36-13-20210206","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2337\/diabetes.46.4.632","article-title":"Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial.","volume":"46","author":"Thompson","year":"1997","journal-title":"Diabetes"},{"key":"R37-13-20210206","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/15209150252924094","article-title":"Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes.","volume":"4","author":"Ratner","year":"2002","journal-title":"Diabetes Technol Ther"},{"key":"R38-13-20210206","doi-asserted-by":"crossref","first-page":"724","DOI":"10.2337\/diacare.25.4.724","article-title":"A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.","volume":"25","author":"Whitehouse","year":"2002","journal-title":"Diabetes Care"},{"key":"R39-13-20210206","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.2337\/diabetes.54.4.1100","article-title":"The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes.","volume":"54","author":"Heptulla","year":"2005","journal-title":"Diabetes"},{"key":"R40-13-20210206","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1210\/jc.2008-2580","article-title":"Twenty-four-hour simultaneous subcutaneous basal-bolus administration of insulin and amylin in adolescents with type 1 diabetes decreases postprandial hyperglycemia.","volume":"94","author":"Heptulla","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R41-13-20210206","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1542\/peds.2008-3750","article-title":"A pilot trial of pramlintide home usage in adolescents with type 1 diabetes.","volume":"124","author":"Kishiyama","year":"2009","journal-title":"Pediatrics"},{"key":"R42-13-20210206","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jpeds.2009.03.012","article-title":"Pramlintide lowered glucose excursions and was well tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study.","volume":"155","author":"Chase","year":"2009","journal-title":"J Pediatr"},{"key":"R43-13-20210206","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.2337\/dc12-0330","article-title":"Effect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with type 1 diabetes.","volume":"35","author":"Weinzimer","year":"2012","journal-title":"Diabetes Care"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0b013e328362fdfb","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:43:19Z","timestamp":1620963799000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008480-201308000-00013"}},"subtitle":["new tools for management of diabetes in youth"],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0b013e328362fdfb","relation":{},"ISSN":["1040-8703"],"issn-type":[{"value":"1040-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]}}}